Eye Diseases > Eyelids
Blepharitis
Evidence-based assessment and management of eyelid margin inflammation. Comprehensive guide covering etiology, pathogenesis, classification, diagnosis, and treatment protocols for optometry practice.
Blepharitis: Inflammation of the eyelid margins with debris, crusting, and gland dysfunction
Blepharitis is a common, chronic inflammatory condition affecting the eyelid margins. It is characterized by inflammation, irritation, and dysfunction of the meibomian glands and/or the eyelid margin itself. Blepharitis is one of the most frequent causes of ocular discomfort and represents a significant challenge in optometric practice due to its chronic nature, high recurrence rate, and impact on patients' quality of life. The condition can affect people of all ages and often coexists with dry eye disease and other ocular surface disorders.
Multifactorial Causes
Blepharitis has a complex, multifactorial etiology involving bacterial colonization, inflammatory processes, and glandular dysfunction:
Bacterial Factors
- Staphylococcus aureus: Most common bacterial pathogen in anterior blepharitis, producing exotoxins that trigger inflammatory response
- Staphylococcus epidermidis: Normal lid flora that can become pathogenic in susceptible individuals
- Propionibacterium acnes: Contributes to meibomian gland dysfunction through lipolytic activity
- Corynebacterium species: May contribute to lipid breakdown and inflammation
Parasitic Factors
- Demodex folliculorum: Mite that lives in lash follicles, found in higher numbers in blepharitis patients
- Demodex brevis: Resides in meibomian glands and sebaceous glands, contributing to gland obstruction
Glandular Dysfunction
- Meibomian gland dysfunction (MGD): Altered lipid secretion and gland obstruction
- Seborrheic gland hyperactivity: Excessive sebum production contributing to debris accumulation
Inflammatory and Immune Factors
- Innate immune dysregulation: Altered inflammatory mediators and cytokines
- Seborrheic dermatitis: Associated skin condition affecting eyelids
- Rosacea: Chronic inflammatory skin disorder with ocular manifestations
- Atopic dermatitis: Allergic inflammatory condition
Pathophysiological Cascade
The development of blepharitis involves a complex cascade of events:
1. Anterior Blepharitis Pathway
- Bacterial colonization: Overgrowth of Staphylococcus species on lid margin and lash base
- Toxin production: Bacterial exotoxins and enzymes (lipases, proteases) damage epithelial cells
- Inflammatory response: Release of inflammatory mediators (IL-1, TNF-α, matrix metalloproteinases)
- Epithelial damage: Breakdown of lid margin epithelium leading to crusting, scaling, and ulceration
- Lash follicle involvement: Inflammation spreads to follicles causing madarosis (lash loss) and irregular growth
2. Posterior Blepharitis (Meibomian Gland Dysfunction) Pathway
- Meibum alteration: Changes in lipid composition (increased melting point, viscosity)
- Gland obstruction: Thickened meibum blocks gland orifices
- Bacterial lipolysis: Bacteria (especially Propionibacterium) break down meibum lipids into irritating free fatty acids
- Gland dropout: Chronic obstruction leads to acinar atrophy and permanent gland loss
- Tear film instability: Deficient or abnormal lipid layer leads to increased tear evaporation and dry eye
3. Demodex-Associated Pathway
- Mite colonization: Demodex mites accumulate in lash follicles and glands
- Mechanical obstruction: Mite bodies and debris block follicles and gland orifices
- Bacterial carrier: Demodex carry bacteria (Bacillus oleronius, Streptococcus) into follicles
- Immune reaction: Host immune response to mites and their exoskeletons causes inflammation
- Follicular keratinization: Chronic inflammation leads to hyperkeratinization and cylindrical dandruff
Vicious Cycle
These pathways create a self-perpetuating cycle where inflammation begets dysfunction, which further promotes bacterial overgrowth and mite infestation, leading to more inflammation. This explains the chronic and recurrent nature of blepharitis.
Anatomical Classification
1. Anterior Blepharitis
Inflammation primarily affecting the anterior lid margin and lash base.
- Staphylococcal blepharitis: Hard crusts, collarettes around lash base, lid margin ulceration
- Seborrheic blepharitis: Greasy, soft scales, less ulceration, often associated with scalp seborrhea
2. Posterior Blepharitis
Inflammation and dysfunction of the meibomian glands located in the tarsal plate.
- Meibomian gland dysfunction (MGD)
- Obstructive (most common): blocked gland orifices
- Hyposecretory: decreased gland output
- Often associated with rosacea, seborrheic dermatitis
3. Mixed Blepharitis
Combination of both anterior and posterior blepharitis (most common in clinical practice).
Etiological Classification
- Infectious: Bacterial (Staphylococcus), parasitic (Demodex), viral (rare)
- Seborrheic: Associated with seborrheic dermatitis
- Meibomian: Primary gland dysfunction
- Allergic: Contact dermatitis, atopic dermatitis
- Rosacea-associated: Ocular rosacea with blepharitis
- Mixed: Combination of multiple factors
Severity Classification
- Mild: Minimal symptoms, slight lid margin inflammation, minor debris
- Moderate: Moderate symptoms and signs, visible crusting, gland dysfunction, affecting quality of life
- Severe: Significant symptoms, marked inflammation, extensive crusting, complications (keratitis, chalazia, trichiasis)
Demographic Factors
- Age: Increasing prevalence with age, especially posterior blepharitis/MGD in adults over 40
- Gender: Some studies suggest higher prevalence in women
- Ethnicity: Asian populations may have higher rates of MGD
Systemic/Dermatologic Conditions
- Rosacea: Strong association with posterior blepharitis and MGD
- Seborrheic dermatitis: Scalp and facial seborrhea
- Atopy: Allergic rhinitis, asthma, eczema
- Diabetes mellitus: May increase susceptibility to infections
- Immunocompromised states: HIV, immunosuppressive medications
- Sjögren's syndrome: Associated with dry eye and MGD
- Thyroid disorders: Particularly hypothyroidism
Environmental and Lifestyle Factors
- Poor eyelid hygiene: Inadequate cleansing of lid margins
- Cosmetics use: Eye makeup, especially if not removed properly
- Contact lens wear: Especially extended wear or poor hygiene
- Environmental factors: Dry, dusty, or polluted environments
- Digital device use: Prolonged screen time reducing blink rate and completeness
- Smoking: May worsen MGD and inflammation
- Dietary factors: Low omega-3 fatty acid intake
Ocular Factors
- Previous ocular surgery: LASIK, cataract surgery may alter tear film
- Chronic topical medication use: Glaucoma medications containing preservatives
- Conjunctivitis: Chronic or recurrent conjunctival inflammation
Medications
- Isotretinoin (Accutane): Reduces meibomian gland secretion
- Antihistamines: May reduce tear production
- Hormonal medications: Including androgens and hormone replacement therapy
Anterior Blepharitis Signs
- Lid margin erythema: Redness and hyperemia of the anterior lid margin
- Collarettes: Cylindrical debris and crusts encircling lash base (pathognomonic for Demodex when prominent)
- Scales and crusting: Adherent debris along lid margin (hard in staphylococcal, soft/greasy in seborrheic)
- Lid margin ulceration: Small ulcers at lash base (more common in staphylococcal)
- Madarosis: Loss of eyelashes, may be focal or diffuse
- Poliosis: Whitening/depigmentation of lashes
- Trichiasis: Misdirected lashes growing toward cornea
- Tylosis: Thickening of the lid margin
Posterior Blepharitis/MGD Signs
- Meibomian gland orifice plugging: Pouting or blocked gland openings at posterior lid margin
- Abnormal meibum quality: Cloudy, thick, or toothpaste-like secretions instead of clear oil
- Reduced meibum expressibility: Difficulty expressing secretions with pressure
- Meibomian gland dropout: Loss of glands visible on meibography (infrared imaging)
- Posterior lid margin telangiectasia: Dilated blood vessels along posterior margin
- Lid margin irregularity: Notching or irregularity of the posterior margin
- Marx line displacement: Epithelial line moves anteriorly
Associated Ocular Surface Signs
- Tear film abnormalities: Reduced tear break-up time (TBUT), foamy tears, debris in tear film
- Conjunctival injection: Redness, especially inferior bulbar and palpebral
- Papillary conjunctivitis: Small papillae on palpebral conjunctiva
- Corneal involvement:
- • Punctate epithelial erosions (PEE), typically inferior
- • Marginal infiltrates (staphylococcal)
- • Phlyctenules
- • Corneal neovascularization (chronic cases)
- • Epithelial basement membrane changes
- Hordeolum (stye): Acute inflammation of lash follicle (external) or meibomian gland (internal)
- Chalazion: Chronic lipogranulomatous inflammation of meibomian gland
Patients with blepharitis typically report chronic, fluctuating symptoms that are often worse in the morning:
Primary Symptoms
- Irritation and burning: Stinging, burning sensation of the eyelids and eyes
- Itching: Pruritus of lid margins, often leads to rubbing and worsening
- Grittiness/foreign body sensation: Sandy, gritty feeling
- Dryness: Sensation of dry eyes, paradoxically may have tearing
- Tearing/watery eyes: Reflex tearing due to ocular surface irritation
- Redness: Red eyelid margins and eyes
- Photophobia: Light sensitivity, especially in cases with corneal involvement
Secondary Symptoms
- Crusting and mattering: Especially upon waking, may cause lashes to stick together
- Flaking: Scales or debris falling from lashes
- Eyelid swelling: Mild edema of lids
- Contact lens intolerance: Difficulty wearing contact lenses, reduced wearing time
- Blurred or fluctuating vision: Due to tear film instability
- Recurrent styes or chalazia: Repeated lumps on eyelids
Symptom Patterns
- Chronicity: Symptoms persist for weeks to years
- Fluctuation: Symptoms wax and wane, often worse during flare-ups
- Bilateral: Usually affects both eyes, though may be asymmetric
- Morning predominance: Often worse upon awakening due to overnight accumulation of debris
- Environmental triggers: May worsen in dry, windy, dusty, or air-conditioned environments
Eyelid Complications
- Hordeolum (stye): Acute infection of lash follicle or meibomian gland requiring warm compresses and possibly antibiotics
- Chalazion: Chronic granulomatous inflammation that may require incision and curettage if persistent
- Trichiasis: Misdirected lashes causing corneal irritation
- Madarosis: Permanent lash loss in chronic severe cases
- Poliosis: Lash depigmentation
- Ectropion/entropion: Lid malposition from chronic inflammation and scarring
- Cicatricial changes: Scarring of lid margin affecting function and appearance
- Preseptal cellulitis: Spread of infection to periorbital tissues (rare but serious)
Ocular Surface Complications
- Chronic dry eye disease: Evaporative dry eye from MGD, leading to persistent ocular discomfort
- Chronic blepharokeratoconjunctivitis: Combined inflammation of lids, conjunctiva, and cornea
- Punctate epithelial erosions (PEE): Superficial corneal epithelial damage
- Marginal keratitis: Peripheral corneal infiltrates adjacent to limbus, often staphylococcal hypersensitivity
- Phlyctenular keratoconjunctivitis: Immune-mediated nodular inflammation
- Corneal scarring: Permanent opacity from chronic or severe keratitis
- Corneal neovascularization: Blood vessel growth into cornea from chronic inflammation
- Corneal ulceration: Rare but serious, risk of infection and perforation
- Recurrent corneal erosion: Repeated episodes of epithelial breakdown
Quality of Life Complications
- Reduced quality of life: Chronic symptoms affecting daily activities, work productivity
- Contact lens intolerance: Inability to wear contact lenses
- Cosmetic concerns: Red, crusty eyelids affecting appearance and self-esteem
- Reading and screen use difficulties: Impaired visual function affecting work and hobbies
Treatment-Related Complications
- Antibiotic resistance: From prolonged or inappropriate antibiotic use
- Steroid-induced complications: Increased intraocular pressure, cataract, secondary infections if steroids used long-term
- Allergic/toxic reactions: To topical medications or preservatives
Blepharitis is frequently associated with systemic conditions, and recognition of these associations is important for comprehensive patient care:
Dermatologic Associations
- Rosacea (Ocular Rosacea):
- • Affects 30-50% of patients with facial rosacea
- • Characterized by facial flushing, telangiectasia, papules, rhinophyma
- • Strongly associated with posterior blepharitis and MGD
- • May require systemic therapy (oral doxycycline, isotretinoin)
- Seborrheic dermatitis:
- • Chronic inflammatory condition affecting sebaceous gland-rich areas
- • Scalp dandruff, facial scaling, especially nasolabial folds, eyebrows
- • Associated with anterior blepharitis with greasy scales
- • May require antifungal therapy (ketoconazole shampoo/cream)
- Atopic dermatitis/eczema:
- • Chronic pruritic inflammatory skin disease
- • Increased risk of staphylococcal blepharitis
- • May have associated atopic keratoconjunctivitis
- Psoriasis:
- • Chronic autoimmune skin condition
- • Lid margin involvement possible
- • Requires coordination with dermatology
Autoimmune and Inflammatory Conditions
- Sjögren's syndrome:
- • Autoimmune disorder affecting lacrimal and salivary glands
- • Associated with aqueous-deficient dry eye and MGD
- • Requires rheumatology co-management
- Inflammatory bowel disease (Crohn's, ulcerative colitis):
- • Extra-intestinal manifestations may include blepharitis
- • Associated with chronic ocular inflammation
Metabolic and Endocrine Associations
- Diabetes mellitus:
- • Increased susceptibility to bacterial infections including blepharitis
- • Impaired wound healing
- • May have more severe or recalcitrant disease
- Thyroid disorders:
- • Hypothyroidism associated with MGD
- • Thyroid eye disease may coexist with blepharitis
- Hormonal changes:
- • Menopause associated with increased MGD prevalence
- • Androgen deficiency may worsen meibomian gland function
Other Systemic Considerations
- Immunocompromised states: HIV/AIDS, immunosuppressive medications may increase infection risk
- Nutritional deficiencies: Essential fatty acid deficiency, vitamin A deficiency may contribute to MGD
Clinical Implications
Recognition of systemic associations is important for:
- Early detection of underlying systemic disease
- Appropriate referral to primary care or specialists
- Coordinated multidisciplinary management
- Optimizing treatment outcomes
- Patient education about disease associations
Diagnosis of blepharitis is primarily clinical, based on history and thorough slit-lamp examination. A systematic approach ensures accurate classification and appropriate management.
Clinical History
- Symptom characterization: Duration, severity, pattern (chronic/recurrent), triggers, relieving factors
- Past ocular history: Previous blepharitis episodes, styes, chalazia, dry eye, contact lens wear
- Medical history: Rosacea, seborrheic dermatitis, atopy, diabetes, autoimmune conditions
- Medications: Current topical/systemic medications, particularly isotretinoin, hormones, glaucoma drops
- Hygiene practices: Lid hygiene routine, cosmetics use, contact lens wear habits
- Environmental/occupational factors: Work environment, screen time, exposure to irritants
Slit-Lamp Examination
Eyelid Margin Evaluation
- Anterior margin: Erythema, scales, collarettes, crusts, ulceration, lash abnormalities
- Posterior margin: Meibomian gland orifice appearance, plugging, telangiectasia, irregularity
- Marx line: Position relative to meibomian gland orifices
Lash Examination
- Collarettes (especially cylindrical debris suggesting Demodex)
- Madarosis (lash loss)
- Poliosis (lash depigmentation)
- Trichiasis (misdirected lashes)
- Irregular growth
Meibomian Gland Assessment
- Meibum expressibility: Apply gentle pressure to evaluate ease of expression (graded 0-3)
- Meibum quality: Assess clarity and consistency (clear liquid oil = normal; cloudy/thick/toothpaste-like = abnormal)
- Number of functional glands: Count glands yielding secretion in lower lid (normal ≥5 of 8 central glands)
- Meibography: Infrared imaging to visualize gland structure and dropout (advanced assessment)
Tear Film Assessment
- Tear break-up time (TBUT): Instill fluorescein, measure time to first break (normal ≥10 seconds; <5 seconds abnormal)
- Tear meniscus height: Reduced in aqueous deficiency, may be normal or increased in evaporative dry eye
- Foam in tear film: Suggests lipid abnormality
- Debris in tears: Floating particles
Conjunctival and Corneal Examination
- Bulbar and palpebral conjunctival injection
- Papillary reaction on palpebral conjunctiva
- Fluorescein staining pattern (inferior PEE common)
- Lissamine green staining (lid wiper epitheliopathy, conjunctival staining)
- Marginal infiltrates or phlyctenules
- Corneal neovascularization or scarring (chronic cases)
Additional Diagnostic Tests
- Lash epilating for Demodex: Epilate 2-3 lashes from each lid, mount in oil on slide, examine under microscope. Finding >2 mites per lash suggests infestation.
- Bacterial culture: Rarely needed; consider in severe, recalcitrant, or atypical cases to guide antibiotic therapy
- Skin biopsy: Very rare; only if suspecting malignancy (basal cell carcinoma, sebaceous carcinoma masquerading as blepharitis)
- Meibography: Non-contact infrared imaging to assess gland morphology and dropout
- Osmolarity testing: Elevated tear osmolarity (>308 mOsm/L) indicates dry eye, often coexistent
- InflammaDry (MMP-9 testing): Point-of-care test for ocular surface inflammation
Grading Systems
Various grading systems exist to standardize assessment:
- Efron grading scale: Photographic reference scale for lid margin redness, roughness, etc.
- MGD grading: Assess meibum quality (0-3), expressibility (0-3), gland dropout on meibography
- OSDI (Ocular Surface Disease Index): Validated symptom questionnaire
Meibography & Advanced Imaging
- Meibography (IR meibographer / LipiView): document gland dropout, acini distortion, and tortuous ducts; percentage gland loss guides treatment intensity.
- Slit-lamp lid margin grading: vascularity, keratinisation, irregularity, foamy secretions.
- Lissamine green / LIPCOF grading: conjunctival staining pattern; elevated LIPCOF score indicates tear meniscus disruption.
- Demodex assessment: cylindrical dandruff (collarettes) at lash bases on high-magnification slit-lamp are pathognomonic for Demodex infestation.
MGD Staging (TFOS DEWS II)
| Stage | Symptoms | Gland Loss | Treatment |
|---|---|---|---|
| Stage 1 | Mild/subclinical; no symptoms | Minimal (<25%) | Lid hygiene, warm compress |
| Stage 2 | Mild symptoms, TBUT <10s | Mild (25–50%) | + Lubricants, omega-3 |
| Stage 3 | Moderate symptoms, PEE | Moderate (50–75%) | + Topical antibiotics/steroids, consider IPL |
| Stage 4 | Severe symptoms, corneal ulceration | Severe (>75% confluent) | Systemic doxycycline, IPL, specialist referral |
Singapore Optometry Scope Note: Optometrists can diagnose blepharitis, educate patients on lid hygiene protocols, and monitor disease progression. Prescription of topical or systemic antibiotics, corticosteroids, or other medications requires referral to ophthalmology or a medical practitioner. Cases with severe complications should be referred to ophthalmology.
Management of blepharitis is multifaceted, chronic, and requires patient education and compliance. Treatment is tailored to the type and severity of blepharitis.
General Principles
- Blepharitis is a chronic condition requiring long-term management, not cure
- Patient education is crucial for compliance and realistic expectations
- Combination therapy is often more effective than monotherapy
- Treatment should address both symptoms and underlying pathophysiology
- Regular follow-up to monitor response and adjust therapy
First-Line Therapy: Lid Hygiene
The cornerstone of blepharitis management, regardless of type:
Warm Compresses
- Purpose: Melt solidified meibum, improve gland secretion
- Method: Apply warm (not hot) compress to closed eyelids for 5-10 minutes
- Frequency: 1-2 times daily
- Options: Warm washcloth, commercial heat masks, microwaveable eye bags
Lid Massage
- Purpose: Express meibum from glands
- Method: Gently massage eyelids in a circular motion or from gland toward lid margin
- Timing: Immediately after warm compresses
Lid Scrubs
- Purpose: Remove debris, scales, bacteria from lid margin
- Method: Gently scrub lid margin and lash base with lid scrub solution on cotton tip or pad
- Products:
- • Commercial lid scrub solutions (e.g., Ocusoft, Systane Lid Wipes)
- • Diluted baby shampoo (no tears formula)
- • Tea tree oil-based products (for Demodex)
- Frequency: 1-2 times daily
Topical Medications
Topical Antibiotics
- Indications: Anterior blepharitis with bacterial colonization, acute exacerbations
- Options:
- • Bacitracin ointment: Apply to lid margin at bedtime
- • Erythromycin ointment: Apply to lid margin at bedtime
- • Azithromycin 1% ophthalmic solution: Twice daily for 2 days, then once daily for several weeks
- Duration: Typically 2-4 weeks for acute treatment; may use intermittently for chronic maintenance
- Caution: Avoid prolonged use due to antibiotic resistance risk
Topical Antibiotics with Anti-inflammatory Properties
- Azithromycin 1%: Has both antimicrobial and anti-inflammatory effects, improves MGD
Topical Corticosteroids
- Indications: Severe inflammation, corneal involvement, symptomatic relief during acute flares
- Options: Loteprednol 0.5%, fluorometholone 0.1%, prednisolone acetate 1%
- Duration: Short courses only (1-2 weeks), taper as inflammation improves
- Monitoring: Check intraocular pressure, watch for steroid complications
- Caution: Risk of IOP elevation, cataract, infection; avoid long-term use
Topical Anti-Demodex Treatments
- Tea tree oil products: 50% tea tree oil or commercial preparations (Cliradex); apply to lid margins daily
- Lotilaner ophthalmic solution 0.25% (Xdemvy): FDA-approved for Demodex blepharitis; twice daily for 6 weeks
- Ivermectin cream: Applied to lid margins
Artificial Tears and Lubricants
- Purpose: Supplement tear film, dilute inflammatory mediators, improve comfort
- Products: Preservative-free artificial tears preferred for frequent use
- Lipid-containing tears: Benefit patients with MGD (e.g., Systane Balance, Refresh Optive Advanced)
- Frequency: As needed, typically 4-6 times daily or more
Systemic Medications
Oral Antibiotics (Tetracyclines)
- Indications: Moderate-to-severe posterior blepharitis/MGD, rosacea, recalcitrant cases
- Mechanism: Anti-inflammatory (inhibit lipases, reduce cytokines), alter meibum composition, antimicrobial
- Options:
- • Doxycycline 50-100 mg PO once or twice daily
- • Minocycline 50-100 mg PO once or twice daily
- • Low-dose doxycycline 40 mg PO daily (sub-antimicrobial dose)
- Duration: Typically 6-12 weeks; may continue at reduced dose for maintenance
- Side effects: GI upset, photosensitivity, candidiasis
- Contraindications: Pregnancy, age <8 years, tetracycline allergy
Other Systemic Options
- Macrolides (azithromycin, erythromycin): Alternative if tetracyclines contraindicated
- Omega-3 fatty acid supplements: Anti-inflammatory; 1-3 grams EPA+DHA daily
- Oral ivermectin: For severe Demodex infestation in consultation with physician
In-Office Procedures
Intense Pulsed Light (IPL) Therapy
- Mechanism: Reduces inflammation, decreases Demodex, liquefies meibum, targets abnormal blood vessels
- Indications: MGD, especially with rosacea
- Protocol: Series of treatments (typically 3-4) spaced 2-4 weeks apart
Thermal Pulsation Therapy (LipiFlow)
- Mechanism: Applies controlled heat and pulsatile pressure to eyelids to evacuate meibomian glands
- Indications: Obstructive MGD
- Protocol: Single 12-minute treatment; may repeat after 6-12 months
Meibomian Gland Expression/Probing
- Expression: Manual expression of glands with specialized instruments (Mastrota paddle, cotton-tip applicators)
- Probing: Insertion of small probe into meibomian gland orifices to clear obstruction (Maskin probe)
- Indications: Severe obstruction, after anesthesia
BlephEx
- Mechanism: Microblepharoexfoliation using rotating sponge to clean lid margins
- Indications: Anterior blepharitis, Demodex
- Protocol: Repeat every 4-6 months
Management by Blepharitis Type
Anterior Blepharitis (Staphylococcal/Seborrheic)
- Lid hygiene (warm compresses, scrubs)
- Topical antibiotic ointment (bacitracin, erythromycin) applied to lid margin
- Short course topical steroid if severe inflammation
- Treat associated seborrheic dermatitis (antidandruff shampoo, topical antifungals)
Posterior Blepharitis/MGD
- Lid hygiene (warm compresses essential, lid massage)
- Artificial tears (lipid-containing)
- Topical azithromycin
- Oral doxycycline or omega-3 supplements for moderate-to-severe cases
- In-office procedures (IPL, LipiFlow, gland expression)
- Manage associated rosacea
Demodex Blepharitis
- Tea tree oil-based lid scrubs or lotilaner ophthalmic solution
- Meticulous lid hygiene
- Lipid-containing artificial tears
- In-office lid debridement (BlephEx)
- Consider oral ivermectin for severe cases (ophthalmology consultation)
Patient Education and Lifestyle Modifications
- Chronic nature: Explain that blepharitis is typically chronic and requires ongoing management
- Compliance: Emphasize importance of daily lid hygiene routine
- Avoid eye rubbing: Reduces inflammation and Demodex transmission
- Cosmetics: Remove eye makeup thoroughly daily; consider avoiding during flares
- Contact lenses: May need to discontinue during active flare; ensure proper lens hygiene
- Environmental modifications: Humidifiers, reduce screen time, take breaks, blink exercises
- Diet: Encourage omega-3 rich foods (fish, flaxseed) and adequate hydration
Referral Indications
- Severe or recalcitrant blepharitis not responding to standard therapy
- Suspected malignancy (unilateral blepharitis, loss of lashes, nodular lesions)
- Complications requiring surgical intervention (severe trichiasis, recurrent chalazia)
- Systemic disease management (dermatology for rosacea, rheumatology for autoimmune conditions)
- Advanced procedures beyond scope of practice
General Prognosis
The prognosis for blepharitis is generally good with appropriate management, though it is important to set realistic expectations:
- Chronic condition: Blepharitis is typically a chronic, relapsing condition rather than a curable disease
- Symptom control: Most patients achieve good symptom control with appropriate therapy and maintenance regimen
- Quality of life: With proper management, most patients can maintain good quality of life and ocular comfort
- No vision threat: Uncomplicated blepharitis rarely threatens vision, though complications may do so
Factors Affecting Prognosis
Favorable Prognostic Factors
- Early diagnosis and treatment initiation
- Good patient compliance with lid hygiene routine
- Mild-to-moderate disease at presentation
- Anterior blepharitis without MGD (generally easier to treat)
- Addressing underlying systemic conditions (rosacea, seborrheic dermatitis)
- No significant meibomian gland dropout
- Younger age
Unfavorable Prognostic Factors
- Poor compliance with treatment regimen
- Severe MGD with significant gland dropout (irreversible)
- Advanced age with longstanding disease
- Coexistent severe dry eye disease
- Uncontrolled systemic conditions (rosacea, seborrheic dermatitis, autoimmune disease)
- Demodex infestation (may require extended treatment)
- Environmental or occupational exposures difficult to modify
- Medication-induced blepharitis (isotretinoin) requiring continuation of offending agent
Long-Term Outlook
- Recurrence: Flare-ups are common even with good control; patients should resume intensive therapy during exacerbations
- Maintenance therapy: Long-term daily lid hygiene is essential to prevent recurrence
- Gland preservation: Early and consistent treatment may prevent or slow meibomian gland dropout
- Complications: With proper management, serious complications (corneal damage, vision loss) are rare
- Associated dry eye: MGD-related dry eye may persist even with blepharitis control, requiring ongoing artificial tear use
Prognosis by Type
Anterior Blepharitis
Generally good response to treatment with lid hygiene and topical antibiotics. Recurrence common if lid hygiene discontinued. Rarely causes permanent damage if managed appropriately.
Posterior Blepharitis/MGD
More challenging to manage than anterior. Significant gland dropout is irreversible. Early and aggressive treatment important to preserve gland function. May require long-term maintenance with warm compresses, oral tetracyclines, or in-office procedures for optimal control.
Demodex Blepharitis
Responds to targeted anti-Demodex therapy but treatment duration is longer (6+ weeks). Reinfection possible without ongoing preventive measures. Prognosis good with consistent treatment.
Patient Counseling Points
- Set realistic expectations: Control, not cure, is the goal
- Daily lid hygiene is a lifelong commitment to maintain control
- Symptom improvement may take weeks; compliance is key
- Early treatment of flare-ups prevents worsening and complications
- Vision loss is rare with appropriate management
- Regular follow-up allows monitoring and treatment adjustment
Several conditions can mimic blepharitis or present with similar lid margin inflammation. Careful examination and history help distinguish between these entities:
1. Allergic Conjunctivitis/Contact Dermatitis
- Features: Eyelid erythema, edema, itching; often bilateral; history of allergen exposure (cosmetics, medications, environmental allergens)
- Differentiation: Acute onset, conjunctival involvement with papillae, resolves with allergen avoidance
2. Atopic Keratoconjunctivitis (AKC)
- Features: Chronic bilateral lid inflammation in patients with atopic history (eczema, asthma); prominent conjunctival injection, papillae, scarring; corneal involvement (shield ulcers, vascularization)
- Differentiation: Prominent allergic component, more severe corneal changes, younger patients
3. Sebaceous Gland Carcinoma
- Features: Rare malignancy masquerading as chronic unilateral blepharitis; typically upper lid; nodular lesion, loss of lashes (madarosis), unresponsive to treatment
- Differentiation: Unilateral, progressive, older patients, chronic unresponsiveness warrants biopsy
- Red flags: Unilateral, fixed lesion, madarosis, age >60, chronic non-response to therapy
4. Basal Cell Carcinoma (BCC)
- Features: Most common eyelid malignancy; typically nodular with rolled borders, central ulceration, telangiectasia; lower lid most common; loss of lashes
- Differentiation: Nodular lesion, unilateral, chronic ulceration, older age, sun exposure history
5. Squamous Cell Carcinoma (SCC)
- Features: Less common than BCC; hyperkeratotic or ulcerated lesion; may arise from actinic keratosis
- Differentiation: More aggressive than BCC, potential for metastasis, biopsy essential
6. Dry Eye Disease (without blepharitis)
- Features: Overlapping symptoms (dryness, irritation, foreign body sensation); may have aqueous deficiency without lid margin disease
- Differentiation: Absence of lid margin inflammation, scales, or MGD; Schirmer test may be reduced
7. Conjunctivitis (Bacterial, Viral, Allergic)
- Features: Conjunctival redness and discharge; acute onset
- Differentiation: Primary involvement is conjunctiva rather than lid margin; acute presentation; discharge pattern (purulent vs. watery vs. mucoid)
8. Cicatricial Pemphigoid
- Features: Chronic autoimmune conjunctival scarring disease; progressive conjunctival shrinkage, symblepharon, fornix shortening, trichiasis
- Differentiation: Scarring and cicatrization prominent, progressive, requires biopsy and immunofluorescence for diagnosis
9. Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)
- Features: Acute severe mucocutaneous reaction (commonly drug-induced); bilateral acute conjunctivitis, lid involvement, skin blistering, systemic illness
- Differentiation: Acute presentation, systemic involvement, skin blistering, conjunctival membrane formation
- Chronic sequelae: May cause chronic blepharitis-like picture after acute phase
10. Angular Blepharitis
- Features: Inflammation primarily at lateral or medial canthi; often due to Moraxella or Staphylococcus; maceration of skin at angles
- Differentiation: Localized to canthi rather than entire lid margin
11. Distichiasis
- Features: Accessory row of lashes growing from meibomian gland orifices; may cause irritation similar to trichiasis complicating blepharitis
- Differentiation: Extra row of lashes rather than misdirected lashes; may be congenital or acquired
12. Molluscum Contagiosum
- Features: Viral infection (poxvirus) causing umbilicated nodules on lid or lid margin; may cause chronic follicular conjunctivitis
- Differentiation: Characteristic umbilicated lesions, often in children or immunocompromised
13. Herpes Simplex or Zoster Blepharitis
- Features: Vesicular eruption along lid margin; may have associated keratitis; unilateral; painful
- Differentiation: Vesicular lesions, acute onset, dermatomal distribution (zoster), herpetic keratitis
Key Distinguishing Features Requiring Further Investigation
- Unilateral presentation: Consider malignancy, infection (HSV, HZV, molluscum)
- Nodular or mass-like lesion: Biopsy to rule out malignancy
- Progressive madarosis: Suspicious for sebaceous cell carcinoma or other malignancies
- Cicatrization and scarring: Consider autoimmune conditions (pemphigoid, SJS/TEN)
- Non-response to standard blepharitis therapy: Re-evaluate diagnosis, consider biopsy
- Systemic signs: Fever, rash, malaise suggest systemic disease or severe infection
Anterior vs posterior distinction drives treatment: Anterior blepharitis (Staphylococcal/Demodex) responds to lid scrubs and targeted anti-infective therapy. Posterior blepharitis (MGD) requires warm compresses, lid massage, and meibomian gland expression — lid hygiene alone is insufficient. Mixing up the diagnosis leads to inadequate and frustrating treatment cycles for both clinician and patient.
MGD is the most common driver of evaporative dry eye worldwide: Per TFOS DEWS II, meibomian gland dysfunction underlies the majority of evaporative dry eye disease. Treat the MGD before escalating to punctal plugs or cyclosporine, as unaddressed MGD limits the effectiveness of all downstream therapies. Stage using meibography and symptom scores (OSDI, DEQ-5).
Demodex collarettes are pathognomonic: Cylindrical dandruff (collarettes) at the base of lashes — distinct from the flaky scales of seborrhoeic blepharitis — indicate Demodex blepharitis. Standard lid hygiene does not eradicate Demodex. Treatment requires tea tree oil-based cleansers (4–5% TTO lid scrubs) or lotilaner ophthalmic solution (CATT-approved). Missed Demodex is a common cause of treatment-resistant anterior blepharitis.
Rosacea-associated blepharitis requires systemic treatment: Posterior blepharitis associated with ocular rosacea responds poorly to topical therapy alone. Systemic doxycycline 100 mg once daily (or sub-antimicrobial 40 mg modified-release) for 6–12 weeks is the mainstay. Refer to ophthalmologist or dermatologist — this is outside optometric prescribing scope. Identify rosacea by facial skin findings (central facial erythema, telangiectasia, rhinophyma).
Asymmetric or ulcerative blepharitis = biopsy to exclude SGC: Blepharitis is almost always bilateral and symmetric. Any markedly unilateral blepharitis, ulcerative lid margin changes, or loss of lashes (madarosis) in a "blepharitis" patient must prompt referral for biopsy to exclude sebaceous gland carcinoma — which classically masquerades as chronic unilateral blepharitis.
Never prescribe prolonged topical steroids without IOP monitoring: Short-course topical steroids have a role in acute exacerbations of blepharokeratoconjunctivitis. However, prolonged use without IOP monitoring risks steroid-response glaucoma, particularly in patients with a family history. Document IOP at baseline and at every steroid review appointment.
Singapore Scope Note: Optometrists in Singapore can manage mild-to-moderate blepharitis with lid hygiene instruction, warm compresses, omega-3 supplementation, and preservative-free lubricants. Topical antibiotics (tobramycin, chloramphenicol) and topical steroids require a prescription — refer to ophthalmologist for these. Intense Pulsed Light (IPL) therapy for MGD is available in Singapore at specialist centres and is outside standard optometric scope; refer to an ophthalmologist or optometrist with IPL certification. Systemic doxycycline requires medical referral. Document MGD stage (TFOS DEWS II Stage 1–4) and anterior blepharitis type at every visit to track treatment response.
- Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis.Cochrane Database Syst Rev. 2012;5(5):CD005556.
- Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009;7(2 Suppl):S1-S14.
- Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials.Ocul Surf. 2014;12(4):273-284.
- Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4):2050-2064.
- Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology. 2017;124(11S):S20-S26.
- Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089-3094.
- Tighe S, Gao YY, Tseng SC. Terpinen-4-ol is the most active ingredient of tea tree oil to kill Demodex mites. Transl Vis Sci Technol. 2013;2(7):2.
- McCulley JP, Shine WE. Meibomian gland function and the tear lipid layer.Ocul Surf. 2003;1(3):97-106.
- Jackson WB. Blepharitis: current strategies for diagnosis and management.Can J Ophthalmol. 2008;43(2):170-179.
- Schaumberg DA, Nichols JJ, Papas EB, Tong L, Uchino M, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011;52(4):1994-2005.
- Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction.Am J Ophthalmol. 1982;94(3):383-387.
- Nicolaides N, Kaitaranta JK, Rawdah TN, Macy JI, Boswell FM 3rd, Smith RE. Meibomian gland studies: comparison of steer and human lipids. Invest Ophthalmol Vis Sci. 1981;20(4):522-536.
- Mastrota KM. Impact of floppy eyelid syndrome in ocular surface and dry eye disease.Optom Vis Sci. 2008;85(9):814-816.
- Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):2006-2049.
- Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922-1929.
- Gupta PK, Stevens MN, Kashyap N, Priestley Y. Preliminary effectiveness and safety results of lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis: a pivotal randomized, vehicle-controlled, double-masked trial. Cornea. 2023;42(3):276-284.
- Holzchuh MH, Hida RY, Moscovici BK, et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin. Am J Ophthalmol. 2011;151(6):1030-1034.
- Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis.Br J Ophthalmol. 1984;68(8):524-528.
- Blackie CA, Korb DR. The diurnal secretory characteristics of individual meibomian glands.Cornea. 2010;29(1):34-38.
- Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report.Ocul Surf. 2017;15(3):276-283.